Hepatitis Monthly

Published by: Kowsar

The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial

Mohsen Razavizade 1 , Raika Jamali 2 , 3 , * , Abbas Arj 1 , Seyyed Mohammad Matini 1 , Alireza Moraveji 4 and Effat Taherkhani 1
Authors Information
1 Internal Medicine Ward, Shahid Beheshti Kashan Hospital, Kashan University of Medical Sciences, Kashan, IR Iran
2 Research Development Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
3 Students Scientific Research Center, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Community Medicine, Kashan University of Medical Sciences, Kashan, IR Iran
Article information
  • Hepatitis Monthly: May 2013, 13 (5); e9270
  • Published Online: May 21, 2013
  • Article Type: Research Article
  • Received: November 25, 2012
  • Revised: February 1, 2013
  • Accepted: March 10, 2013
  • DOI: 10.5812/hepatmon.9270

To Cite: Razavizade M, Jamali R, Arj A, Matini S M, Moraveji A, et al. The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial, Hepat Mon. 2013 ;13(5):e9270. doi: 10.5812/hepatmon.9270.

Abstract
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2012; 11(1): 18-27[PubMed]
  • 2. Butt AS, Abbas Z, Jafri W. Hepatocellular carcinoma in pakistan: where do we stand? Hepat Mon. 2012; 12(10 HCC)[DOI][PubMed]
  • 3. Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int. 2007; 6(6): 572-8[PubMed]
  • 4. Jin HB, Gu ZY, Yu CH, Li YM. Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. Hepatobiliary Pancreat Dis Int. 2005; 4(3): 389-92[PubMed]
  • 5. Gharouni M, Rashidi A. Association between fatty liver and coronary artery disease: Yet to explore. Hepat Mon. 2007; 2007(4, Autumn): 243-44
  • 6. Kelishadi R, Poursafa P. Obesity and air pollution: global risk factors for pediatric non-alcoholic fatty liver disease. Hepat Mon. 2011; 11(10): 794
  • 7. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol. 2008; 14(18): 2867-71[PubMed]
  • 8. Dai HF, Shen Z, Yu CH, Zhang XC, Li YM. Epidemiology of fatty liver in an islander population of China: a population-based case-control study. Hepatobiliary Pancreat Dis Int. 2008; 7(4): 373-8[PubMed]
  • 9. Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166). J Dig Dis. 2011; 12(1): 38-44[DOI][PubMed]
  • 10. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001; 34(4 Pt 1): 738-44[DOI][PubMed]
  • 11. Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab. 2007; 21(4): 687-710[DOI][PubMed]
  • 12. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50(9): 2094-9[PubMed]
  • 13. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004; 39(1): 188-96[DOI][PubMed]
  • 14. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004; 2(12): 1107-15[PubMed]
  • 15. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007; 46(2): 424-9[DOI][PubMed]
  • 16. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135(4): 1176-84[DOI][PubMed]
  • 17. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355(22): 2297-307[DOI][PubMed]
  • 18. Al-Gharabally A, O'Brien CB, Acosta RC. A pilot study of pioglitazone for the treatment of non-alcoholic fatty liver disease. Hepat Mon. 2007; 7(3): 131-7
  • 19. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008; 5(3): 157-67[DOI][PubMed]
  • 20. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia. 2006; 49(3): 434-41[DOI][PubMed]
  • 21. Magalotti D, Marchesini G, Ramilli S, Berzigotti A, Bianchi G, Zoli M. Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. Dig Liver Dis. 2004; 36(6): 406-11[DOI][PubMed]
  • 22. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005; 21(7): 871-9[DOI][PubMed]
  • 23. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001; 358(9285): 893-4[PubMed]
  • 24. Nair S, Diehl AM, Wiseman M, Farr GH, Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004; 20(1): 23-8[DOI][PubMed]
  • 25. Ghamar-Chehreh ME, Khedmat H, Amini M, Taheri S. Predictive Factors for Ultrasonographic Grading of Nonalcoholic Fatty Liver Disease. Hepat Mon. 2012; 12(11)
  • 26. Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2012; 11(5): 513-20[PubMed]
  • 27. Jamali R, Pourshams A, Amini S, Deyhim MR, Rezvan H, Malekzadeh R. The upper normal limit of serum alanine aminotransferase in Golestan Province, northeast Iran. Arch Iran Med. 2008; 11(6): 602-7[PubMed]
  • 28. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009; 137(3): 865-72[DOI][PubMed]
  • 29. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004; 27(6): 1487-95[PubMed]
  • 30. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100(5): 1082-90[DOI][PubMed]
  • 31. Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther. 2008; 30(6): 1168-76[DOI][PubMed]
  • 32. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135(1): 100-10[DOI][PubMed]
  • 33. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003; 52(6): 1364-70[PubMed]
  • 34. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004; 53(8): 2169-76[PubMed]
  • 35. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012; 107(6): 811-26[DOI][PubMed]
  • 36. Ipekci SH, Basaranoglu M, Sonsuz A. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2003; 36(4): 371[PubMed]
  • 37. Khosravi S, Alavian SM, Zare A, Daryani NE, Fereshtehnejad SM, Keramati MR, et al. Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings. Hepat Mon. 2011; 11(6): 452-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader